HLB Co. Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: -0.036x

HLB Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, HLB Co. Ltd (028300) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-17.75 Billion ≈ $-12.03 Million USD) by net assets (₩493.87 Billion ≈ $334.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of HLB Co. Ltd (2010–2025)

Cash flow conversion efficiency of HLB Co. Ltd from 2010 to 2025. This chart illustrates how HLB Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 028300 stock price and chart for real-time trading data and today's change.

HLB Co. Ltd Cash Flow Conversion Ratio Explained

HLB Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

HLB Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of HLB Co. Ltd ranked by their cash flow conversion efficiency. Also see HLB Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Asbury Automotive Group Inc
NYSE:ABG
0.057x
Pepkor Holdings Ltd
JSE:PPH
0.077x
Quebecor Inc
TO:QBR-A
0.192x
Huaneng Power International Inc
F:HUP1
0.034x
Hoegh Autoliners ASA
OL:HAUTO
0.458x
Lazard Ltd
NYSE:LAZ
0.291x
All Winner Technology Co Ltd
SHE:300458
0.041x
PTT OIL+RET.BUS.-NVDR- 10
F:7F80
-0.360x

Annual Cash Flow Conversion Efficiency for HLB Co. Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of HLB Co. Ltd from 2010 to 2025. Review how much free cash does HLB Co. Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩494.41 Billion
≈ $335.06 Million
₩-92.59 Billion
≈ $-62.75 Million
-0.187x +5.55%
2024-12-31 ₩576.57 Billion
≈ $390.73 Million
₩-114.31 Billion
≈ $-77.47 Million
-0.198x -3.41%
2023-12-31 ₩582.25 Billion
≈ $394.58 Million
₩-111.63 Billion
≈ $-75.65 Million
-0.192x -97.86%
2022-12-31 ₩637.94 Billion
≈ $432.32 Million
₩-61.82 Billion
≈ $-41.89 Million
-0.097x +22.86%
2021-12-31 ₩435.96 Billion
≈ $295.44 Million
₩-54.77 Billion
≈ $-37.11 Million
-0.126x -6.64%
2020-12-31 ₩479.75 Billion
≈ $325.12 Million
₩-56.51 Billion
≈ $-38.30 Million
-0.118x +55.24%
2019-12-31 ₩184.89 Billion
≈ $125.30 Million
₩-48.66 Billion
≈ $-32.97 Million
-0.263x -57.63%
2018-12-31 ₩174.68 Billion
≈ $118.38 Million
₩-29.16 Billion
≈ $-19.76 Million
-0.167x +32.42%
2017-12-31 ₩77.24 Billion
≈ $52.35 Million
₩-19.08 Billion
≈ $-12.93 Million
-0.247x -115.97%
2016-12-31 ₩88.75 Billion
≈ $60.14 Million
₩-10.15 Billion
≈ $-6.88 Million
-0.114x -1436.44%
2015-12-31 ₩84.65 Billion
≈ $57.37 Million
₩724.49 Million
≈ $490.97K
0.009x +104.96%
2014-12-31 ₩23.02 Billion
≈ $15.60 Million
₩-3.97 Billion
≈ $-2.69 Million
-0.173x -601.71%
2011-12-31 ₩21.19 Billion
≈ $14.36 Million
₩728.78 Million
≈ $493.89K
0.034x +164.06%
2010-12-31 ₩23.31 Billion
≈ $15.79 Million
₩303.53 Million
≈ $205.70K
0.013x --

About HLB Co. Ltd

KQ:028300 Korea Biotechnology
Market Cap
$3.60 Billion
₩5.32 Trillion KRW
Market Cap Rank
#4247 Global
#89 in Korea
Share Price
₩40000.00
Change (1 day)
+0.76%
52-Week Range
₩25650.00 - ₩68200.00
All Time High
₩120800.00
About

HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, inclu… Read more